Camlin Fine Sciences (CAMLINFINE) | Financial Analysis & Statements
Camlin Fine Sciences Ltd. Small-cap Basic Materials
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
4.2B
Gross Profit
1.9B
44.07%
Operating Income
21.1M
0.50%
Net Income
-106.8M
-2.52%
EPS (Diluted)
₹-0.53
Balance Sheet Metrics
Total Assets
20.2B
Total Liabilities
11.5B
Shareholders Equity
8.7B
Debt to Equity
1.31
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Camlin Fine Sciences Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 16.4B | 16.0B | 16.7B | 14.0B | 11.7B |
| Cost of Goods Sold | 8.7B | 9.4B | 8.3B | 7.7B | 5.9B |
| Gross Profit | 7.7B | 6.6B | 8.4B | 6.3B | 5.8B |
| Gross Margin % | 46.8% | 41.3% | 50.3% | 45.1% | 49.2% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 579.7M | 597.7M | 568.7M | 577.2M | 453.1M |
| Other Operating Expenses | 2.9B | 2.6B | 3.8B | 2.6B | 2.1B |
| Total Operating Expenses | 3.5B | 3.2B | 4.4B | 3.1B | 2.5B |
| Operating Income | 1.6B | 713.3M | 1.6B | 1.1B | 1.6B |
| Operating Margin % | 9.5% | 4.5% | 9.7% | 7.6% | 13.6% |
| Non-Operating Items | |||||
| Interest Income | 104.4M | 17.7M | 10.9M | 17.5M | 14.5M |
| Interest Expense | 775.1M | 676.2M | 411.3M | 292.3M | 395.2M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 494.7M | -992.4M | 803.8M | 939.8M | 1.1B |
| Income Tax | 665.0K | 56.3M | 405.7M | 336.1M | 397.4M |
| Effective Tax Rate % | 0.1% | 0.0% | 50.5% | 35.8% | 37.8% |
| Net Income | -1.6B | -1.0B | 398.1M | 603.7M | 653.6M |
| Net Margin % | -9.7% | -6.6% | 2.4% | 4.3% | 5.6% |
| Key Metrics | |||||
| EBITDA | 2.1B | 1.2B | 2.0B | 1.8B | 1.9B |
| EPS (Basic) | ₹-8.03 | ₹-5.45 | ₹3.45 | ₹4.61 | ₹4.13 |
| EPS (Diluted) | ₹-8.03 | ₹-5.45 | ₹3.41 | ₹4.53 | ₹3.68 |
| Basic Shares Outstanding | 173142349 | 170193218 | 167315188 | 140836278 | 123448779 |
| Diluted Shares Outstanding | 173142349 | 170193218 | 167315188 | 140836278 | 123448779 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Camlin Fine Sciences Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 1.0B | 802.5M | 937.4M | 1.1B | 755.2M |
| Short-term Investments | 392.7M | 9.7M | 14.5M | 209.8M | 476.3M |
| Accounts Receivable | 3.3B | 2.9B | 3.0B | 3.0B | 2.7B |
| Inventory | 5.3B | 5.1B | 5.7B | 3.7B | 3.2B |
| Other Current Assets | 81.6M | 32.0M | 45.8M | 43.8M | 40.3M |
| Total Current Assets | 11.8B | 10.0B | 10.9B | 8.9B | 7.9B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 35.4M | 35.3M | 35.5M | 34.9M | 34.8M |
| Goodwill | 1.1B | 1.1B | 1.2B | 1.3B | 1.1B |
| Intangible Assets | 102.3M | 128.1M | 134.1M | 231.9M | 241.2M |
| Long-term Investments | - | 0 | 18.3M | 34.0M | 997.0K |
| Other Non-Current Assets | -1.0K | 54.1M | 45.1M | 156.6M | 171.3M |
| Total Non-Current Assets | 8.4B | 9.5B | 9.7B | 9.1B | 6.9B |
| Total Assets | 20.2B | 19.5B | 20.6B | 18.0B | 14.8B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.8B | 3.2B | 2.9B | 2.3B | 1.6B |
| Short-term Debt | 3.9B | 3.3B | 3.8B | 2.4B | 2.7B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 159.4M | 327.8M | 94.5M | 38.7M | 8.2M |
| Total Current Liabilities | 8.5B | 7.3B | 7.9B | 6.0B | 4.8B |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.9B | 3.5B | 4.2B | 4.0B | 2.8B |
| Deferred Tax Liabilities | 33.1M | 68.4M | 151.0M | 103.1M | 63.1M |
| Other Non-Current Liabilities | 1.8M | 3.5M | 3.9M | 4.6M | - |
| Total Non-Current Liabilities | 3.0B | 3.6B | 4.4B | 4.4B | 2.9B |
| Total Liabilities | 11.5B | 10.9B | 12.4B | 10.4B | 7.7B |
| Equity | |||||
| Common Stock | 187.9M | 167.5M | 157.1M | 157.0M | 127.5M |
| Retained Earnings | 996.4M | 2.3B | 3.0B | 2.3B | 1.5B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 8.7B | 8.6B | 8.2B | 7.7B | 7.1B |
| Key Metrics | |||||
| Total Debt | 6.8B | 6.8B | 8.0B | 6.5B | 5.5B |
| Working Capital | 3.4B | 2.7B | 2.9B | 3.0B | 3.2B |
Balance Sheet Composition
Camlin Fine Sciences Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -1.6B | -992.4M | 803.8M | 939.8M | 1.1B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 2.8M | 90.0K | 23.6M | 73.9M | 45.3M |
| Working Capital Changes | -784.2M | 316.7M | -1.4B | 41.7M | -659.3M |
| Operating Cash Flow | -1.4B | 271.7M | -157.0M | 1.4B | 847.3M |
| Investing Activities | |||||
| Capital Expenditures | -424.5M | -600.2M | -1.4B | -2.1B | -838.7M |
| Acquisitions | - | - | 0 | -655.4M | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -424.5M | -600.2M | -1.4B | -2.8B | -838.7M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | -281.3M | -138.5M | -7.1M | -54.2M |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 2.1B | -273.7M | 389.7M | 637.0M | 37.3M |
| Free Cash Flow | -157.2M | 784.1M | -934.1M | -683.4M | 335.1M |
| Net Change in Cash | 226.0M | -602.2M | -1.2B | -806.2M | 45.8M |
Cash Flow Trend
Camlin Fine Sciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
18.52
Forward P/E
22.06
Price to Book
2.25
Price to Sales
1.16
PEG Ratio
0.03
Profitability Ratios
Profit Margin
-3.45%
Operating Margin
1.16%
Return on Equity
-15.89%
Return on Assets
-6.87%
Financial Health
Current Ratio
1.36
Debt to Equity
78.10
Beta
0.53
Per Share Data
EPS (TTM)
₹-0.79
Book Value per Share
₹47.62
Revenue per Share
₹95.13
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CAMLINFINE | 23.1B | 18.52 | 2.25 | -15.89% | -3.45% | 78.10 |
| Asian Paints | 2.4T | 62.11 | 12.16 | 18.28% | 11.10% | 17.61 |
| Pidilite Industries | 1.4T | 62.22 | 14.87 | 20.85% | 16.19% | 4.54 |
| Tanfac Industries | 49.6B | 66.26 | 14.61 | 28.25% | 10.85% | 9.28 |
| Gulf Oil Lubricants | 48.1B | 13.85 | 2.91 | 23.50% | 8.88% | 29.57 |
| Neogen Chemicals | 44.8B | 222.22 | 5.46 | 4.41% | 2.41% | 141.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.





